MedPath

Comparison of treatment outcomes between letrozole with Gonadotropins in Polycystic Ovarian Syndrome patients

Phase 2
Conditions
Disorders of other endocrine glands.
Polycystic ovarian syndrome
Registration Number
IRCT201106271233N2
Lead Sponsor
Vice Chancellor for research-Guilan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
130
Inclusion Criteria

having PCOS according to Rotterdam criteria and, infertility for one year, age 20-39 years old
Exclusion criteria: tubal obstruction, infertility with male factor, hypersensitivity to Clomiphene Citrate or letrozole, presence of diabetes, thyroid or kidney disease, ovarian drilling, ovarian cyst on day 3 of menstrual cycle

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Endometrial thickness. Timepoint: Every 2-3 days. Method of measurement: Transvaginal ultrasonography.
Secondary Outcome Measures
NameTimeMethod
Follicles greater than 16mm. Timepoint: Every 2-3 days. Method of measurement: Transvaginal sonography.;Clinical pregnancy. Timepoint: 14days after IUI. Method of measurement: Ultrasonography two weeks after positive BHCG for finding gestetaional sac.;Chemical pregnancy. Timepoint: 14days after IUI. Method of measurement: bHCG measurment.;E2 level. Timepoint: Once in a cycle. Method of measurement: On the day of HCG injection by blood sampling.;Cancellation rate. Timepoint: Every 2-3 days. Method of measurement: Transvaginal sonograhy.;The number of Gonadotropines used. Timepoint: at the end of the cycle. Method of measurement: Number of Ampoules.
© Copyright 2025. All Rights Reserved by MedPath